Background: Rheumatoid arthritis (RA) is a complex inflammatory disease that has features of atherosclerosis and cognitive decline. Although the relationship between atherosclerosis and cognitive impairment has been studied and replicated, whether cognitive deficits in RA can be attributed to their atherosclerotic changes is not well understood. Objectives: This study investigated the cognitive function in patients with RA using the Korean version of the Consortium to Establish a Registry for Alzheimer's disease (CERAD-K) neuropsychological battery and evaluated whether cognitive function was affected by the carotid arterial atherosclerosis. Methods: We examined seventy RA patients and forty healthy controls. RA activity was assessed by disease activity score with 28 joints-erythrocyte sedimentation rate (DAS28-ESR) and objective memory impairment was defined as a performance score of 1.5 standard deviations below the respective agespecific, education-specific, and sex-specific normative means for at least one of the four episodic memory tests in CERAD-K; the Word List Memory, Word List Recall, Word List Recognition, and Constructional Recall tests [1] . Carotid arteries were scanned for the presence of plaque and intima-media thickness (IMT). We assessed potential risk factors of cognitive impairment in RA patients using regression analyses. Results: Of the CERAD-K subtests, there were a significant difference between the RA patients and healthy controls in verbal fluency (12.97±3.73 vs 15.48±4.57, respectively; p=0.004) and Boston Naming Test (11.50±2.08 vs 12.30±1.77, respectively; p=0.035). Carotid ultrasound revealed significantly more plaques in the RA patients than in the healthy controls (39% vs 15%, respectively; p=0.017). RA patients with memory impairment have significantly higher score of DAS28-ESR (4.14±0.99 vs 2.60±0.88, respectively; p<0.001), age (65.71±7.71 vs 58.50±11.33, respectively; p=0.009), and mean cIMT (0.56±0.10 vs 0.50±0.08, respectively; p=0.027) compared to RA patients without memory impairment. In multivariable regression analysis, CERAD-K total score showed a significant negative correlation with age (β=-0.415, p<0.001) or DAS28-ESR (β=-4.685, p<0.001), but no correlation was found between CERAD-K total score and presence of plaque or cIMT (Table 1) .
Conclusions:
Our results indicate that disease activity of RA and aging contribute to cognitive impairment, but there was no association between cognitive function and clinical or subclinical carotid atherosclerotic changes in RA patients. Background: Patient global assessment (PGA) of disease activity is included in a large number of composite indices of disease activity and definitions of remission in Rheumatoid Arthritis (RA). However, the actual question is formulated in a variety of different ways according to the instrument considered. Objectives: To evaluate how 6 different formulations of PGA affect patient estimates and impact upon disease activity and remission rates as assessed by 4 Disease Activity Indices. Methods: Consecutive RA patients followed in a Rheumatology outpatient department were included in this cross-sectional study. Data collection comprised: 28 joint counts (tender and swollen), C-reactive protein (CRP) and 6 different PGA formulations. The chosen formulations were the ones stated in the: v1) Portuguese National Registry Reuma.pt, the locally used formulation; v2) ACR/EULAR provisional definition of remission (considered in this study as the "standard"); v3) CDAI and SDAI; v4) Disease Activity Score (DAS28) assessment of general health; v5) DAS28 assessment of disease activity (the currently used); v6) one, exploratory, developed by the investigators, including idiomatic cultural expressions. ACR/EULAR Boolean criteria, CDAI, SDAI, and DAS28-CRP (4v) were used to test how these 6 PGA formulations change the rates of remission. PGA differences were assessed by descriptive analyses (including patients with PGA ≤10 and ≤20mm) and Bland-Altman test. Results: In total, 193 patients were included (82% female, mean (SD) age of 59 (13) years, mean disease duration of 12 (9) years and 31% under biologics). The average PGA ranged from 42.3 (25.3) to 48.1 (26.7)mm as measured in different formulations. The ACR/EULAR (v2) formulation yielded the largest proportion of 
